AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30087427 — intervention group
Group type: COMPARATOR
Intervention: Community centers treatment
Number of subjects: 0
Study 26879896 — intervention group
Group type: EXPERIMENTAL
Intervention: ViSC Social Competence Program
Number of subjects: 2042
Study 25259553 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 88
Study 25259553 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 88
Study 22745114 — intervention group
Group type: EXPERIMENTAL
Intervention: D5W-LA group (6 mL of D5W followed by 6 mL of lidocaine 1.5% with epinephrine 1:200,000)
Number of subjects: 95
Study 22745114 — intervention group
Group type: COMPARATOR
Intervention: LA group (6 mL of lidocaine 1.5% with epinephrine 1:200,000 alone)
Number of subjects: 95
Study 22745114 — intervention group
Group type: EXPERIMENTAL
Intervention: D5W-LA group
Number of subjects: 95
Study 22745114 — intervention group
Group type: COMPARATOR
Intervention: LA group
Number of subjects: 95
Study 19967762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook‐Swartz implantable Doppler probe
Number of subjects: 40
Study 19967762 — intervention group
Group type: COMPARATOR
Intervention: Clinical monitoring alone
Number of subjects: 40
Study 21475452 — intervention group
Group type: EXPERIMENTAL
Intervention: El-Menia air inflated balloon
Number of subjects: 240
Study 21475452 — intervention group
Group type: COMPARATOR
Intervention: Ecbolics and uterine massage (Control)
Number of subjects: 240
Study 14990557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydrated + Water ad libitum (Hy+W)
Number of subjects: 10
Study 14990557 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated + Water ad libitum (Eu+W)
Number of subjects: 10
Study 14990557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydrated + No Water (Hy+NW)
Number of subjects: 10
Study 14990557 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated + No Water (Eu+NW)
Number of subjects: 10
Study 11275671 — intervention group
Group type: EXPERIMENTAL
Intervention: 228‐ppm fluoride controlled‐release rinse (CR rinse)
Number of subjects: 13
Study 11275671 — intervention group
Group type: EXPERIMENTAL
Intervention: 228‐ppm fluoride NaF rinse
Number of subjects: 13
Study 11275671 — intervention group
Group type: COMPARATOR
Intervention: Water rinse
Number of subjects: 13
Study 9870619 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive head turning (70 degrees to either side)
Number of subjects: 16
Study 9870619 — intervention group
Group type: COMPARATOR
Intervention: Facing forward
Number of subjects: 16
Study 8304603 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic bladder aspiration
Number of subjects: 100
Study 8304603 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheterization
Number of subjects: 100
Study 2656736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.2-1 mg once weekly
Number of subjects: 48
Study 2656736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.2-0.5 mg twice weekly
Number of subjects: 48
Study 2656736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.4-0.6 mg three times weekly
Number of subjects: 48
Study 2656736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.3-0.6 mg once weekly
Number of subjects: 48
Study 2656736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 2-3 mg weekly
Number of subjects: 48
Study 2656736 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline (various schedules)
Number of subjects: 48
Study 2656736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30939361 — intervention group
Group type: EXPERIMENTAL
Intervention: AUT00063 (800 mg capsules daily for 28 days)
Number of subjects: 212
Study 30939361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 28089564 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak oxygen consumption (VO2peak) measured in a symptom‐limited ramp exercise test
Number of subjects: 113
Study 28089564 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and sex factors
Number of subjects: 113
Study 28089564 — intervention group
Group type: EXPERIMENTAL
Intervention: History of cardiovascular disease and pulmonary disease
Number of subjects: 113
Study 28089564 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity level, hypertension, smoking, and overweight
Number of subjects: 113
Study 28089564 — intervention group
Group type: EXPERIMENTAL
Intervention: History of stroke and stroke characteristics
Number of subjects: 113
Study 25727860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 20, 40 or 80 mg three times daily
Number of subjects: 277
Study 25727860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 25727860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 277
Study 25727860 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <60 ml min(‐1) 1.73 m(‐2)
Number of subjects: 277
Study 23259764 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal 1 (50g CH, 8.9g fat, 3.3g protein)
Number of subjects: 17
Study 23259764 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal 2 (50g CH, 37.4g fat, 28.9g protein)
Number of subjects: 17
Study 20828634 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) delivered via telephone, 6 sessions
Number of subjects: 216
Study 20828634 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (details not specified)
Number of subjects: 216
Study 18579168 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.03 g/kg/day)
Number of subjects: 22
Study 18579168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16899034 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Urge Questionnaire (AUQ) under neutral conditions
Number of subjects: 248
Study 16899034 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Urge Questionnaire (AUQ) during cue-elicited urge state
Number of subjects: 248
Study 15085979 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimexolone 1% ophthalmic suspension (27 subjects)
Number of subjects: 48
Study 15085979 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1% (21 subjects)
Number of subjects: 48
Study 15085979 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimexolone 1% ophthalmic suspension
Number of subjects: 48
Study 15085979 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 48
Study 10686218 — intervention group
Group type: COMPARATOR
Intervention: 600 mg testosterone alone (T; n = 11)
Number of subjects: 26
Study 10686218 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oestradiol (TE10; n = 7)
Number of subjects: 26
Study 10686218 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oestradiol (TE20; n = 8)
Number of subjects: 26
Study 10165315 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 0
Study 10165315 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 0
Study 8374686 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH therapy administered 3 times a week with a total weekly dose of 0.5 IU/kg
Number of subjects: 22
Study 8374686 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH therapy administered 6 times a week with a total weekly dose of 0.5 IU/kg
Number of subjects: 22
Study 8374686 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (1.5 micrograms/day for 4 days)
Number of subjects: 22
Study 3529360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 1 g/day for 4 weeks (C4)
Number of subjects: 48
Study 3529360 — intervention group
Group type: COMPARATOR
Intervention: 1 week of cimetidine treatment followed by 3 weeks of placebo (C1 + P)
Number of subjects: 48
Study 3529360 — intervention group
Group type: COMPARATOR
Intervention: C1 + P
Number of subjects: 48
Study 28328086 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment condition (EXP; N = 11)
Number of subjects: 21
Study 28328086 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control condition (TAU; N = 10)
Number of subjects: 21
Study 26439386 — intervention group
Group type: COMPARATOR
Intervention: OFD + placebo gel (group 1)
Number of subjects: 105
Study 26439386 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF + HA with OFD (group 2)
Number of subjects: 105
Study 26439386 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg RSV gel + PRF + HA with OFD (group 3)
Number of subjects: 105
Study 25089930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential fluoxetine (16-week course initiated 8 weeks prequit)
Number of subjects: 206
Study 25089930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential fluoxetine
Number of subjects: 206
Study 25089930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 22048712 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 min of supervised cycle training at 65% of VO(2max), three times per week for 4 weeks)
Number of subjects: 30
Study 22048712 — intervention group
Group type: COMPARATOR
Intervention: Control (maintaining normal levels of physical activity)
Number of subjects: 30
Study 19561363 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 208
Study 18401673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored newsletters based on self-determination theory (SDT) and motivational interviewing (MI) principles
Number of subjects: 512
Study 18401673 — intervention group
Group type: COMPARATOR
Intervention: Control newsletters tailored only on demographic and social cognitive variables
Number of subjects: 512
Study 18401673 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (younger participants)
Number of subjects: 512
Study 18401673 — intervention group
Group type: COMPARATOR
Intervention: Control group (younger participants)
Number of subjects: 512
Study 18401673 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (older participants)
Number of subjects: 512
Study 18401673 — intervention group
Group type: COMPARATOR
Intervention: Control group (older participants)
Number of subjects: 512
Study 15793249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (30-45 microg) with usual insulin bolus-to-carbohydrate ratio
Number of subjects: 8
Study 15793249 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased insulin bolus-to-carbohydrate ratio with minidose glucagon rescue injections
Number of subjects: 8
Study 15793249 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 8
Study 15046689 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg every 3 weeks for 15 months
Number of subjects: 0
Study 15046689 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 0
Study 15046689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10630070 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of mesoglycan (1 or 2 vials/day)
Number of subjects: 40
Study 10630070 — intervention group
Group type: COMPARATOR
Intervention: Vegetal stimulins (control group)
Number of subjects: 40
Study 7498384 — intervention group
Group type: EXPERIMENTAL
Intervention: Conical contact pad
Number of subjects: 0
Study 7498384 — intervention group
Group type: COMPARATOR
Intervention: Flat contact pad
Number of subjects: 0
Study 2127834 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily for 28 days
Number of subjects: 20
Study 2127834 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 20
Study 7194395 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 150 ml/kg per day
Number of subjects: 28
Study 7194395 — intervention group
Group type: COMPARATOR
Intervention: Infusion of 60 ml/kg per day
Number of subjects: 28
Study 30852278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 100
Study 30852278 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 27810317 — intervention group
Group type: EXPERIMENTAL
Intervention: XG-102 900 μg
Number of subjects: 145
Study 27810317 — intervention group
Group type: EXPERIMENTAL
Intervention: XG-102 90 μg
Number of subjects: 145
Study 27810317 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 145
Study 26218050 — intervention group
Group type: EXPERIMENTAL
Intervention: ChannelFree (CF) processing
Number of subjects: 20
Study 26218050 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide Dynamic Range Compression (WDRC) processing
Number of subjects: 20
Study 26218050 — intervention group
Group type: COMPARATOR
Intervention: Unaided condition
Number of subjects: 20
Study 23695545 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (omeprazole 20 mg bid + amoxicillin 1 g bid + clarithromycin 500 mg bid for 7 days)
Number of subjects: 281
Study 23695545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (omeprazole 20 mg bid + amoxicillin 1 g bid for 5 days, followed by omeprazole 20 mg bid + tinidazole 500 mg bid + clarithromycin 500 mg bid for an additional 5 days)
Number of subjects: 281
Study 21292420 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) therapy for an average of 6.6 years
Number of subjects: 513
Study 21292420 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonusers of CEE therapy)
Number of subjects: 513
Study 19052141 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 8
Study 19052141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17466655 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer
Number of subjects: 140
Study 17466655 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant treatment
Number of subjects: 140
Study 17466655 — intervention group
Group type: COMPARATOR
Intervention: Inhaler
Number of subjects: 140
Study 15238969 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment plus reminder
Number of subjects: 231
Study 15238969 — intervention group
Group type: COMPARATOR
Intervention: Appointment only
Number of subjects: 231
Study 11379675 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ropivacaine
Number of subjects: 120
Study 11379675 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ropivacaine plus 75 microg clonidine
Number of subjects: 120
Study 11379675 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ropivacaine plus 15 microg clonidine
Number of subjects: 120
Study 11379675 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ropivacaine plus 45 microg clonidine
Number of subjects: 120
Study 9182213 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 831
Study 9182213 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine alone
Number of subjects: 831
Study 9182213 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine
Number of subjects: 831
Study 8351757 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Bacillus Calmette‐Guérin (BCG) therapy with 20 intravesical instillations in 1 year
Number of subjects: 49
Study 8351757 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Bacillus Calmette‐Guérin (BCG) therapy with 20 intravesical instillations in 1 year and 6 intradermal inoculations
Number of subjects: 49
Study 8351757 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intradermal inoculations)
Number of subjects: 49
Study 3606929 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine infusion
Number of subjects: 17
Study 3606929 — intervention group
Group type: COMPARATOR
Intervention: Vehicle infusion
Number of subjects: 17
Study 2526573 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 386
Study 2526573 — intervention group
Group type: COMPARATOR
Intervention: No surgery (control group)
Number of subjects: 386
Study 31471960 — intervention group
Group type: EXPERIMENTAL
Intervention: Authors' familiarity with predatory journals
Number of subjects: 249
Study 31471960 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of Beall's list of predatory journals
Number of subjects: 249
Study 31471960 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief about publication in a predatory journal
Number of subjects: 249
Study 31471960 — intervention group
Group type: EXPERIMENTAL
Intervention: Future publication intentions
Number of subjects: 249
Study 31471960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of peer review awareness
Number of subjects: 249
Study 31471960 — intervention group
Group type: EXPERIMENTAL
Intervention: Editors' awareness of their journal listing
Number of subjects: 249
Study 26119203 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous interspinous process spacer (IPS) treatment
Number of subjects: 80
Study 23988791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation for 12 weeks
Number of subjects: 38
Study 23988791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 21610482 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-handed unit configuration
Number of subjects: 8
Study 21610482 — intervention group
Group type: COMPARATOR
Intervention: Mirrored unit configuration
Number of subjects: 8
Study 19620913 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 whole body vibration sessions per week
Number of subjects: 73
Study 16095786 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention intervention
Number of subjects: 114
Study 16095786 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 15481651 — intervention group
Group type: EXPERIMENTAL
Intervention: kami-shoyo-san
Number of subjects: 113
Study 15481651 — intervention group
Group type: COMPARATOR
Intervention: antidepressants
Number of subjects: 113
Study 11747248 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of inhaled salbutamol (Albuterol) from the original Glaxo product
Number of subjects: 20
Study 11747248 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of inhaled salbutamol (Albuterol) from generic product 1
Number of subjects: 20
Study 11747248 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of inhaled salbutamol (Albuterol) from generic product 2
Number of subjects: 20
Study 11747248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9242858 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Adaptation intervention
Number of subjects: 50
Study 9242858 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 50
Study 7506173 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide 5 mg/kg/day
Number of subjects: 100
Study 7506173 — intervention group
Group type: COMPARATOR
Intervention: mefenamic acid 5 mg/kg divided into 2 or 3 daily doses
Number of subjects: 100
Study 3813056 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric 0.5% bupivacaine (3 ml)
Number of subjects: 90
Study 3813056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric 0.5% bupivacaine (3 ml)
Number of subjects: 90
Study 3813056 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 30897585 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (20 min before, during, and 20 min after endotracheal suctioning)
Number of subjects: 98
Study 30897585 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine suctioning)
Number of subjects: 98
Study 29189539 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.25 mg/kg IV loading dose followed by 15 μg/kg/min infusion)
Number of subjects: 50
Study 29189539 — intervention group
Group type: COMPARATOR
Intervention: Saline (normal saline infusion)
Number of subjects: 50
Study 26825757 — intervention group
Group type: EXPERIMENTAL
Intervention: modified WHO ORS with PHGG 15 g/L
Number of subjects: 126
Study 26825757 — intervention group
Group type: COMPARATOR
Intervention: modified WHO ORS without PHGG (control)
Number of subjects: 126
Study 23648370 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 23648370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22051585 — intervention group
Group type: EXPERIMENTAL
Intervention: Active interferential current
Number of subjects: 40
Study 22051585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham) interferential current
Number of subjects: 40
Study 22051585 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study 19092347 — intervention group
Group type: EXPERIMENTAL
Intervention: Heller laparoscopic myotomy plus anterior fundoplication (Dor procedure)
Number of subjects: 144
Study 19092347 — intervention group
Group type: COMPARATOR
Intervention: Heller laparoscopic myotomy plus total fundoplication (floppy-Nissen procedure)
Number of subjects: 144
Study 16943652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia therapy for 24 hours
Number of subjects: 39
Study 16943652 — intervention group
Group type: COMPARATOR
Intervention: Pretrial clinical evaluation phase
Number of subjects: 39
Study 14578238 — intervention group
Group type: EXPERIMENTAL
Intervention: DOIT (Diabetes Outpatient Intensive Treatment program)
Number of subjects: 167
Study 14578238 — intervention group
Group type: COMPARATOR
Intervention: EDUPOST (standard diabetes care with quarterly educational mailings)
Number of subjects: 167
Study 10343151 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone (200 mg)
Number of subjects: 18
Study 10343151 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 7498102 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐erucic acid rapeseed oil (RO)
Number of subjects: 12
Study 7498102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil (SO)
Number of subjects: 12
Study 7498102 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter oil (BO)
Number of subjects: 12
Study 1941390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 5 mg/kg
Number of subjects: 178
Study 1941390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Number of subjects: 178
Study 1941390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (both dosages)
Number of subjects: 178